Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amgen, Inc. (AMGN) vs McDonald's Corp (MCD) Price & Performance

Amgen, Inc.Trade
McDonald's CorpTrade

Price performance (Past 24H)

Key statistics

Amgen, Inc. vs McDonald's Corp — how do they compare? Amgen, Inc. trades at $411.88 (market cap $224.14B), while McDonald's Corp trades at $270.86 (market cap $194.00B). The key difference: Amgen, Inc. is the larger of the two by market cap, and McDonald's Corp pays the higher dividend (2.71%). Which is the better fit depends on your goals.

AMGNMCD
Market Cap
$224.14B$194.00B
Sector
HealthConsumer Cyclical
52-Week High
$417.20$341.06
52-Week Low
$271.18$262.80
Enterprise Value
$267.45B$247.77B
Dividend Yield
2.43%2.71%
Volume
2,230,036

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amgen, Inc.

Amgen (AMGN) trades at $417.20, up 1.52% with strong technical momentum as price approaches resistance near $421. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $36.75 billion and 2026 projected at $38.1 billion, supported by strong performance from key products like Tezspire and Repatha.

Amgen presents a compelling growth story with raised 2026 guidance and strong product pipeline, though elevated valuation ratios (P/E 25.73, P/S 5.91) and high debt levels ($56.55 billion long-term debt) warrant caution. Analyst consensus remains bullish with 59% buy ratings and $394.69 price target, but current price trades above consensus target, suggesting near-term consolidation potential.

McDonald's Corp

McDonald's (MCD) trades at $273.72, down 0.28% on the day, with a neutral technical signal and strong fundamentals including a 31.72% net margin and consistent earnings beats. The company recently unveiled its 'McDonald's NEXT' growth strategy focusing on automation and menu innovation to drive future performance. Revenue growth remains steady, with 2025 revenue at $26.89 billion.

Outlook is positive with a consensus price target of $322.45 offering 17.8% upside, supported by 60% analyst buy ratings. Risks include inflationary pressures on franchisee margins and high long-term debt of $38.42 billion. The stock presents a value opportunity with stable dividends and strategic initiatives aimed at enhancing competitiveness.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Read more on AMGN

About McDonald's Corp

McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.

Read more on MCD